All Insights
Showing 433 - 444 of 723
Regulatory Outlook
Regulatory Outlook | February 2022
Welcome to the Regulatory Outlook providing you with high-level summaries of important forthcoming regulatory developments to help you navigate the
Dispute resolution
Ukraine crisis: The UK and the EU announce more sanctions
Additional sanctions are the likely precursor to further measures by the UK and the EU as well as the US
Dispute resolution
The UK consults on signing the fledgling Singapore Convention on Mediation
The UN treaty will become more effective as more countries sign up, but, in the meantime, how useful is it?
Competition, antitrust and trade
Half-time analysis: what's next for the European Super League?
The 'superleaguers' and UEFA and FIFA's legal clash hinges on an EU court ruling that could shape the future of
Financial Services
Operational resilience: the final countdown is on for the new UK regime
The go-live date for the new rules approaches on 31 March: what does the Financial Conduct Authority expect from firms?
Intellectual property
Vagisil versus Vagisan and prefixes: takeaways for healthcare brand owners
Vagisan was found by the High Court to infringe the Vagisil trade mark and a proposed rebrand to 'Dr Wolff's
Competition, antitrust and trade
Competition Outlook 2022
Antitrust activity across Europe is set for another busy year.
Tax
HMRC updates VAT guidance on early termination fees and compensation payments
The new policy will apply from 1 April and provides much-needed clarity on supplies related to construction and real estate
IT and data
UK international data transfer agreements laid before Parliament
Businesses relieved of uncertainty regarding data transfers outside of the UK as the ICO signals that agreements are almost finalised
Brexit
How the UK regulates sectors and markets: five new principles
The government has set out principles based on a sovereign approach, leading from the front, proportionality, what works and high
Real estate
'All reasonable endeavours': what does it mean?
High Court decision suggests that 'all reasonable endeavours' goes well beyond reasonable endeavours
Life Sciences and Healthcare
Medical device advertising in Italy: is authorisation by the Ministry of Health still required?
Italian Ministry of Health departs from harmonised EU regulatory framework on advertising medical devices by continuing authorisation regime
